The additional value of integrated PET/CT over PET in initial lymph node staging of esophageal cancer

Oncology Reports

Volumn 20, Issue 4, 2008, Pages 857-862

  Kato, Hiroyuki ^a   Kimura, Hitoshi ^a   Nakajima, Masanobu ^a   Sakai, Makoto ^a   Sano, Akihiko ^a   Tanaka, Naritaka ^a   Inose, Takanori ^a   Faried, Ahmad ^a   Saito, Kana ^a   Ieta, Keisuke ^a   Sohda, Makoto ^a   Fukai, Yasuyuki ^a   Miyazaki, Tatsuya ^a   Masuda, Norihiro ^a   Fukuchi, Minoru ^a   Ojima, Hitoshi ^a   Tsukada, Katsuhiko ^a   Oriuchi, Noboru ^a   Endo, Keigo ^a   Kuwano, Hiroyuki ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

18F fluorodeoxyglucose; Computed tomography; Esophageal cancer; Lymph node staging; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEMALE; HUMAN; INTERMETHOD COMPARISON; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; LYMPH NODES; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 54949108564     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or_00000083     Document Type: Article

References (37)

1. Bar-Shalom R, Valdivia AY and Blaufox MD: PET imaging in oncology. Semin Nucl Med 30:150-185, 2000.
2. Bares R, Klever P, Hauptmann S, et al: F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology 192: 79-86, 1994.
3. Inoue T, Kim EE, Komaki R, et al: Detecting recurrent or residual lung cancer with FDG-PET. J Nucl Med 36: 788-793, 1995.
4. Ahuja V, Coleman RE, Herndon J and Patz EF Jr: The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with non-small cell lung carcinoma. Cancer 83: 918-924, 1998.
5. Coleman RE: PET in lung cancer. J Nucl Med 40: 814-820, 1999.
6. Block MI, Patterson GA, Sundaresan RS, et al: Improvement in staging of esophageal cancer with the addition of positron emission tomography. Ann Thorac Surg 64: 770-776, 1997.
7. Luketich JD, Schauer PR, Meltzer CC, et al: Role of positron emission tomography in staging esophageal cancer. Ann Thorac Surg 64: 765-769, 1997.
8. Flanagan FL, Dehdashti F, Siegel BA, et al: Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 168: 417-424, 1997.
9. Rankin SC, Taylor H, Cook GJ and Mason R: Computed tomography and positron emission tomography in the pre-operative staging of oesophageal carcinoma. Clin Radiol 53: 659-665, 1998.
10. Yeung HW, Macapinlac HA, Mazumdar M, Bains M, Finn RD and Larson SM: FDG-PET in esophageal cancer. Incremental value over computed tomography. Clin Positron Imaging 2: 255-260, 1999.
11. Flamen P, Lerut A, Van Cutsem E, et al: Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 18: 3202-3210, 2000.
12. Yoon YC, Lee KS, Shim YM, Kim BT, Kim K and Kim TS: Metastasis to regional lymph nodes in patients with esophageal squamous cell carcinoma: CT versus FDG PET for presurgical detection prospective study. Radiology 227: 764-770, 2003.
13. van Westreenen HL, Westerterp M, Bossuyt PM, et al: Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol 22: 3805-3812, 2004.
14. Skehan SJ, Brown AL, Thompson M, Young JE, Coates G and Nahmias C: Imaging features of primary and recurrent esophageal cancer at FDG-PET. Radiographics 20: 713-723, 2000.
15. Flamen P, Lerut A, Van Cutsem E, et al: The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer. J Thorac Cardiovasc Surg 120: 1085-1092, 2000.
16. Kato H, Miyazaki T, Nakajima M, Fukuchi M, Manda R and Kuwano H: Value of positron emission tomography in the diagnosis of recurrent oesophageal carcinoma. Br J Surg 91: 1004-1009, 2004.
17. Brucher BL, Weber W, Bauer M, et al: Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography. Ann Surg 233: 300-309, 2001.
18. Flamen P, Van Cutsem E, Lerut A, et al: Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer. Ann Oncol 13: 361-368, 2002.
19. Weber WA, Ott K, Becker K, et al: Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 19: 3058-3065, 2001.
20. Kato H, Kuwano H, Nakajima M, et al: Usefulness of positron emission tomography for assessing the response of neoadjuvant chemoradiotherapy in patients with esophageal cancer. Am J Surg 184: 279-283, 2002.
21. Kato H, Kuwano H, Nakajima M, et al: Comparison between positron emission tomography and computed tomography in the use of the assessment of esophageal carcinoma. Cancer 94: 921-928, 2002.
22. Kato H, Miyazaki T, Nakajima M, et al: The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer 103: 148-156, 2005.
23. Kato H, Fukuchi M, Miyazaki T, et al: Positron emission tomography in esophageai cancer. Esophagus 2: 111-121, 2005.
24. Bar-Shalom R, Yefremov N, Guralnik L, et al: Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med 44: 1200-1209, 2003.
25. Lardinois D, Weder W, Hany TF, et al: Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348: 2500-2507, 2003.
26. Schoder H, Yeung HW, Gonen M, Kraus D and Larson SM: Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology 231: 65-72, 2004.
27. Cohade C, Osman M, Leal J and Wahl RL: Direct comparison of 18FFDG PET and PET/CT in patients with colorectal carcinoma. J Nucl Med 44: 1797-1803, 2003.
28. Freudenberg LS, Antoch G, Schutt P, et al: FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging 31: 325-329, 2004.
29. Bar-Shalom R, Guralnik L, Tsalic M, et al: The additional value of PET/CT over PET in FDG imaging of oesophageal cancer. Eur J Nucl Med Mol Imaging 32: 918-924, 2005.
30. Jadvar H, Henderson RW and Conti PS: 2-deoxy-2-[F-18] fluoro-D-glucose-positron emission tomography/computed tomography imaging evaluation of esophageal cancer. Mol Imaging Biol 8: 193-200, 2006.
31. Blodgett TM, Meltzer CC and Townsend DW: PET/CT: form and function. Radiology 242: 360-385, 2007.
32. Sobin LH and Wittekind C (eds). TNM classification of malignant tumors, 6th edition. John Wiley & Sons, New York, 2002.
33. Japanese Society for Esophageal Diseases. Guidelines for the clinical and pathological studies on carcinoma of the esophagus. 10th edition. Kanehara, Tokyo, 2007.
34. Beck JR: Likelihood ratios. Another enhancement of sensitivity and specificity. Arch Pathol Lab Med 110: 685-686, 1986.
35. Dwyer AJ: Matchmaking and McNemar in the comparison of diagnostic modalities. Radiology 178: 328-330, 1991.
36. Erasmus JJ and Munden RF: The role of integrated computed tomography positron-emission tomography in esophageal cancer: staging and assessment of therapeutic response. Semin Radiat Oncol 17: 29-37, 2007.
37. Yuan S, Yu Y, Chao KS, et al: Additional value of PET/CT over PET in assessment of locoregionai lymph nodes in thoracic esophageal squamous cell cancer. J Nucl Med 47: 1255-1259, 2006.